Provided by Tiger Trade Technology Pte. Ltd.

Aclaris Therapeutics

4.41
-0.8500-16.16%
Post-market: 4.460.0500+1.13%19:34 EDT
Volume:5.18M
Turnover:24.09M
Market Cap:649.15M
PE:-7.52
High:5.18
Open:5.18
Low:4.35
Close:5.26
52wk High:6.60
52wk Low:1.74
Shares:147.20M
Float Shares:101.00M
Volume Ratio:2.42
T/O Rate:5.13%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5861
EPS(LYR):-0.5300
ROE:-59.10%
ROA:-28.98%
PB:5.21
PE(LYR):-8.32

Loading ...

Aclaris Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 07

Aclaris Therapeutics Q1 net loss widens on higher R&D spending

Reuters
·
May 07

BRIEF-Aclaris Therapeutics Q1 EPS USD -0.15 Vs. IBES Estimate USD -0.16

Reuters
·
May 07

Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update

GlobeNewswire
·
May 07

Aclaris Therapeutics Is Maintained at Overweight by Piper Sandler

Dow Jones
·
May 06

Aclaris Therapeutics Initiated at Buy by Guggenheim

Dow Jones
·
May 05

Aclaris Therapeutics price target raised to $11 from $7 at Piper Sandler

TIPRANKS
·
May 05

Aclaris Therapeutics initiated with a Buy at Guggenheim

TIPRANKS
·
May 05

Damora Therapeutics names Brian Burkavage principal financial officer, accounting officer

Reuters
·
May 05

Aclaris Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview

Reuters
·
May 04

JTL Industries Wins ACRS Nod, Tightens Grip on Global Structural Steel Markets

TIPRANKS
·
May 04

Aclaris Therapeutics Is Maintained at Outperform by Wedbush

Dow Jones
·
Apr 30

Aclaris Therapeutics price target raised to $10 from $8 at Wedbush

TIPRANKS
·
Apr 29

Wedbush Raises Price Target on Aclaris Therapeutics to $10 From $8, Keeps Outperform Rating

MT Newswires Live
·
Apr 29

Aclaris Therapeutics’ ATI-052 antibody shows PK efficacy in Phase 1a trial

TIPRANKS
·
Apr 28

BRIEF-Aclaris Therapeutics Says Positive Full Top Line Results From Phase 1A Clinical Trial Of ATI-055

Reuters
·
Apr 28

Aclaris Therapeutics Inc - Enrollment Ongoing in Phase 1B Trials of ATI-052; Top Line Results Expected H2 2026

THOMSON REUTERS
·
Apr 28

Aclaris Therapeutics Inc - ATI-052 Well Tolerated With Favorable Safety Profile in Phase 1a Trial

THOMSON REUTERS
·
Apr 28

Aclaris Therapeutics Inc: No Impact of Anti-Drug Antibodies (Ada) on Pk or Pd Has Been Observed in This Trial

THOMSON REUTERS
·
Apr 28

BML Capital’s Braden Leonard sells 300,000 Aclaris shares for $1.36 million

Reuters
·
Apr 28